Key Takeaways
- • Blackstone has engaged Goldman Sachs to run a sell-side auction for Nucleus Network, its clinical trials business, with a target valuation exceeding $1 billion.
- • Nucleus Network generated approximately $60 million in EBITDA across operations in Australia, the UK, and the United States, representing a mature, cash-generative asset after four years under Blackstone ownership.
- • Bain Capital is among the competitive bidders for the asset, signaling strong institutional interest in clinical research infrastructure as a healthcare sector consolidation play.
- • The divestiture will free up capital for Blackstone to redeploy toward other investment priorities, including its $13.1 billion Asia private equity fund that exceeded its $10 billion fundraising target.
- • Goldman Sachs' selection followed a formal advisor interview process conducted in January 2026, underscoring the transaction's scale and strategic importance in the healthcare PE market.
Summary
Blackstone is advancing the sale of Nucleus Network, its clinical research organization, through a formal auction process managed by Goldman Sachs. The transaction targets a valuation in excess of $1 billion and represents a significant exit from the healthcare services sector after Blackstone's four-year hold period. Goldman Sachs secured the sell-side mandate following competitive interviews with investment banks in January 2026, positioning the firm to execute a structured auction process designed to maximize competitive tension among bidders.
Nucleus Network operates a diversified clinical trials platform spanning three major geographies: Australia, the United Kingdom, and the United States. The business generated approximately $60 million in EBITDA across these operations, demonstrating stable, recurring revenue generation characteristic of essential healthcare infrastructure. This earnings profile supports the $1 billion-plus valuation target and signals to potential acquirers a mature, de-risked asset with established operational infrastructure and customer relationships.
Bain Capital has emerged as a prominent bidder in the competitive auction, alongside other strategic and financial acquirers evaluating the asset. The interest from Bain and comparable sponsors reflects broader institutional appetite for healthcare services platforms, particularly those with visibility to clinical trial volumes driven by pharmaceutical and biotech R&D spending. The competitive nature of the auction process is expected to maximize proceeds for Blackstone and validate the underlying business economics.
For Blackstone, the Nucleus Network divestiture aligns with active capital redeployment across its portfolio. The firm recently closed its largest Asia-focused private equity fundraise to date, securing $13.1 billion for its Asia PE fund—exceeding the initial $10 billion target. Proceeds from the Nucleus Network sale will enhance flexibility in executing this geographic expansion strategy and addressing other portfolio priorities within its broader alternative asset management mandate.
The transaction is expected to complete within the current fiscal cycle, subject to customary regulatory approvals and closing conditions typical of healthcare M&A transactions of this scale.
Nucleus Network operates a diversified clinical trials platform spanning three major geographies: Australia, the United Kingdom, and the United States. The business generated approximately $60 million in EBITDA across these operations, demonstrating stable, recurring revenue generation characteristic of essential healthcare infrastructure. This earnings profile supports the $1 billion-plus valuation target and signals to potential acquirers a mature, de-risked asset with established operational infrastructure and customer relationships.
Bain Capital has emerged as a prominent bidder in the competitive auction, alongside other strategic and financial acquirers evaluating the asset. The interest from Bain and comparable sponsors reflects broader institutional appetite for healthcare services platforms, particularly those with visibility to clinical trial volumes driven by pharmaceutical and biotech R&D spending. The competitive nature of the auction process is expected to maximize proceeds for Blackstone and validate the underlying business economics.
For Blackstone, the Nucleus Network divestiture aligns with active capital redeployment across its portfolio. The firm recently closed its largest Asia-focused private equity fundraise to date, securing $13.1 billion for its Asia PE fund—exceeding the initial $10 billion target. Proceeds from the Nucleus Network sale will enhance flexibility in executing this geographic expansion strategy and addressing other portfolio priorities within its broader alternative asset management mandate.
The transaction is expected to complete within the current fiscal cycle, subject to customary regulatory approvals and closing conditions typical of healthcare M&A transactions of this scale.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.